We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is AngioDynamics (ANGO - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
AngioDynamics is a member of the Medical sector. This group includes 1003 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. AngioDynamics is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for ANGO's full-year earnings has moved 26% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that ANGO has returned about 0.9% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 7.8% on average. This shows that AngioDynamics is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is ANIXA BIOSCIENCES INC (ANIX - Free Report) . The stock is up 14.7% year-to-date.
The consensus estimate for ANIXA BIOSCIENCES INC's current year EPS has increased 10.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, AngioDynamics belongs to the Medical - Instruments industry, a group that includes 86 individual companies and currently sits at #79 in the Zacks Industry Rank. On average, this group has lost an average of 14% so far this year, meaning that ANGO is performing better in terms of year-to-date returns.
ANIXA BIOSCIENCES INC, however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 509-stock industry is ranked #75. The industry has moved -11.4% so far this year.
Investors with an interest in Medical stocks should continue to track AngioDynamics and ANIXA BIOSCIENCES INC. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is AngioDynamics (ANGO - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
AngioDynamics is a member of the Medical sector. This group includes 1003 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. AngioDynamics is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for ANGO's full-year earnings has moved 26% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that ANGO has returned about 0.9% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 7.8% on average. This shows that AngioDynamics is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is ANIXA BIOSCIENCES INC (ANIX - Free Report) . The stock is up 14.7% year-to-date.
The consensus estimate for ANIXA BIOSCIENCES INC's current year EPS has increased 10.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, AngioDynamics belongs to the Medical - Instruments industry, a group that includes 86 individual companies and currently sits at #79 in the Zacks Industry Rank. On average, this group has lost an average of 14% so far this year, meaning that ANGO is performing better in terms of year-to-date returns.
ANIXA BIOSCIENCES INC, however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 509-stock industry is ranked #75. The industry has moved -11.4% so far this year.
Investors with an interest in Medical stocks should continue to track AngioDynamics and ANIXA BIOSCIENCES INC. These stocks will be looking to continue their solid performance.